HIV/HCV Coinfection
| |
Emerging HIV-1 resistance to tipranavir and darunavir in patients with
virological failure to
first-generation protease inhibitors in Taiwan.
Hsieh SM, Chang SY, Hung CC, et al
Int J STD AIDS. 2011
Nov;22(11):617-20.
Abstract
Interpretation of Genotypic Resistance to Predict
Darunavir/Ritonavir Failure in Antiretroviral Experienced Patients.
Sterrantino G, Zaccarelli M, Trotta M,
et
al
J Acquir Immune Defic Syndr. 2011 Nov 7
Abstract
The higher barrier of darunavir and tipranavir resistance for HIV-1 protease.
Wang Y, Liu Z, Brunzelle JS,
et
aL
Biochem Biophys Res Commun. 2011 Sep
9;412(4):737-42
Abstract
A
WEEK-IN-REVIEW FEATURED REPORT
Comparison of Drug Resistance Scores for Tipranavir in PI-naive
HIV-1 Infected Patients with B and Non-B Subtypes.
Stürmer M, Stephan C, Gute P,
et al
Antimicrob Agents Chemother. 2011 Aug 8.
Abstract
Susceptibility of HIV-1 to tipranavir and other antiretroviral
agents in treatment-experienced patients:
The UTILIZE Study.
Baxter JD, Bhatti L, Coakley E,
et al
Curr HIV Res.
2010 Jun;8(4):347-54.
Abstract |
Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and
virtual phenotypic
resistance patterns: an independent cohort analysis of clinical isolates highly
resistant to all
other protease inhibitors.
Talbot A, Grant P, Taylor J,
et al
Antimicrob Agents Chemother. 2010
Jun;54(6):2473-9
Abstract |
Drug Resistance Mutations in HIV-Infected Patients Failing Tipranavir
and
Darunavir in the Spanish Drug Resistance Database.
Poveda E, Anta L, Blanco JL, et al
Antimicrob Agents Chemother.
2010 May 17.
Abstract |
Predicting Tipranavir and Darunavir Resistance using Genotypic, Phenotypic
and Virtual Phenotypic Resistance Patterns: An Independent Cohort Analysis
of Clinical Isolates Highly Resistant to All Other Protease Inhibitors.
Talbot A, Grant P, Taylor J,
et al
Antimicrob Agents Chemother. 2010 Apr 5
Abstract |
FULL-TEXT PDF ARTICLE
Impact
of first-line protease inhibitors on predicted resistance to tipranavir in
HIV-1-infected
patients with virological failure.
Hsieh SM, Chang SY, Hung CC, et al
BMC Infect Dis.
2009 Sep 14;9(1):154.
Paper |
Reversal of major genotypic tipranavir mutations under long-term treatment with
tipranavir/ritonavir itself with
very limited optimized background, during deep salvage antiretroviral therapy.
Sabbatani S, Manfredi R, Fulgaro C, Bon I.
Curr HIV Res.
2009 May;7(3):311-3.
Abstract |
Tipranavir/ritonavir genotypic resistance score in protease
inhibitor-experienced patients.
Marcelin AG, Masquelier B, Descamps D, et al
Antimicrob Agents Chemother. 2008 Jul
14.
Abstract |
New resistance score for tipranavir .
Poveda E
AIDS Rev. 2008 Apr-Jun;10(2):127
Abstract
|
Selection and characterization of HIV-1 showing reduced susceptibility to
the non-peptidic
protease inhibitor tipranavir.
Doyon L, Tremblay S, Bourgon L, et al
Antiviral Res. 2005 Aug 22;
Abstract |
| |
FULL-TEXT ARTICLE
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was
Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in
Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational,
Multicenter Trial.
Cooper DA, Cordery DV, Zajdenverg R,
et al
PLoS
One. 2016 Jan
5;11(1):e0144917.
Paper
Efficacy
and Safety of Tipranavir Co-Administered with Ritonavir in HIV-1-Infected
Children and Adolescents: 5 Years of Experience
Salazar JC, Cahn P, Negra MD, et al
Pediatr Infect Dis J.
2013 Aug 29
Abstract
Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients:
Observational Data
from the Randomized POTENT Trial.
Elgadi MM, Piliero PJ.
Drugs R D. 2011
Oct 18.
Abstract
Tipranavir in highly antiretroviral treatment-experienced patients: Results from
a French prospective cohort.
Allavena C, Flandre P, Pugliese P. et al
Scand J Infect Dis. 2011 Aug 19.
Abstract
Virologic and Immunologic Effectiveness of Tipranavir/Ritonavir (TPV/r)- Versus
Darunavir/Ritonavir
(DRV/r)-Based Regimens in Clinical Practice.
Antoniou T, Raboud JM, Diong C, et al
J Int Assoc Physicians AIDS Care
2010 Nov-Dec;9(6):382-9.
Abstract
|
Factors predictive of successful darunavir/ritonavir-based therapy in highly
antiretroviral-
experienced HIV-1-infected patients (the DARWEST study).
Delaugerre C, Buyck JF, Peytavin G,
et al
J Clin Virol.
2010 Mar;47(3):248-52.
Abstract
|
Efficacy and safety of a salvage regimen based on tipranavir,
enfuvirtide and three
nucleoside analogues in HIV1 infected patients with clinical
progression: 96-week
evaluation.
Sozio F, Polilli E, D Annunzio M, Falconi L, et al
Infez
Med. 2009 Dec;17(4):228-35.
Abstract
|
Successful virological outcome in an HIV-infected individual with a
three-class resistant variant
and an insertion in the
protease genome with a Tipranavir based regimen.
Panagopoulos P, Paraskevis D,
Antoniadou A, et al
Ir J Med Sci. 2008 Sep 10.
Abstract
|
A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics
of the Nonpeptidic
Protease Inhibitor Tipranavir in Treatment-Naive HIV-1-Infected Patients.
McCallister S, Valdez H, Curry K,et al
J Acquir Immune Defic Syndr. 2004 Apr
20;35(4):376-382
Abstract |
|
A liquid chromatography-tandem mass spectrometry assay for
quantification of nevirapine,
indinavir, atazanavir, amprenavir, saquinavir, ritonavir,
lopinavir, efavirenz, tipranavir, darunavir
and maraviroc in the plasma of patients infected with HIV.
Martin J, Deslandes G, Dailly E, et al
J Chromatogr B Analyt Technol Biomed Life Sci.
2009 Aug 3
Abstract |
Low trough levels of tipranavir in a combination antiretroviral
therapy of tipranavir/ritonavir and tenofovir
require therapeutic drug monitoring.
Langmann P, Winzer R, Schirmer D, et al
Eur J Med Res. 2008 Oct
27;13(10):469-71.
Abstract
|
Simultaneous quantification of the new HIV protease inhibitors
atazanavir and tipranavir in
human plasma by high-performance
liquid chromatography coupled with electrospray ionization
tandem mass spectrometry.
Crommentuyn KM, Rosing H, Hillebrand MJ, et al
J Chromatogr B Analyt Technol Biomed Life
Sci. 2004 May 25;804(2):359-67.
Abstract |
|
|
Animal
Studies
Tipranavir Main Page
Main
New/Newsworthy
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
